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A B S T R A C T
There have been no reports of successful resuscitation using nitroglycerin (NTG) for cardiac arrest due to
deﬁnitive coronary vasospasm. A 42-year-old female was brought to the Emergency Department in
ventricular ﬁbrillation after being found collapsed with the consumption of misoprostol. NTG, a potent
coronary arterial dilator, not typically used in the management of cardiac arrest, was administered after
27 min of resuscitation efforts following advanced cardiac life support. NTG aided in the return of
spontaneous circulation during a ventricular ﬁbrillation cardiac arrest in the setting of prostaglandin use.
<Learning objective: Nitroglycerin is not typically employed in the management of cardiac arrest. We
report successful cardiac resuscitation after administration of intravenous nitroglycerin during a
prolonged cardiac arrest event secondary to coronary artery vasospasm in the setting of recent
misoprostol ingestion. Nitroglycerin may have a role in cardiac arrest in the setting of coronary
vasospasm.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Journal of Cardiology Cases
jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eIntroduction
Cardiac arrest in the setting of coronary artery vasospasm is an
uncommon phenomenon [1]. Medications, such as epinephrine
and vasopressin that are included in the standard Advanced
Cardiac Life Support (ACLS) algorithm for cardiac arrest, have been
known to induce coronary vasospasm [2]. Nitroglycerin (NTG), on
the other hand, is a potent coronary arterial dilator and is routinely
used for ischemic discomfort in the setting of acute coronary
syndrome (ACS) but is not typically employed in the management
of cardiac arrest [2]. To our knowledge, there have been no reports
of successful resuscitation using NTG for cardiac arrest due to
deﬁnitive coronary vasospasm and data regarding NTG use during
cardiac arrest are limited. Two reports, one from 1984, and one
from 2009, document the use of intravenous NTG in the setting of
cardiac arrest [3,4]. These reports however, involved patients with
signiﬁcant coronary atherosclerosis demonstrated by cardiac* Corresponding author at: Yale-New Haven Hospital, 20 York Street, New Haven,
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightcatheterization or undetermined coronary anatomy due to lack
of catheterization entirely. Here, we report a case of successful
cardiac resuscitation after administration of intravenous NTG
during a prolonged cardiac arrest event secondary to coronary
artery vasospasm in the setting of recent misoprostol ingestion.
Case report
A 42-year-old female with a medical history of hypertension
was brought to the Emergency Department via Emergency Medical
Services after being found collapsed with the consumption of
misoprostol. A home medication list included norethindrone
0.35 mg daily and misoprostol 200 mcg sublingual once in
preparation for a gynecologic procedure. Downtime to initiation
of cardiopulmonary resuscitation (CPR) was approximately 5 min
and the presenting rhythm was pulseless ventricular ﬁbrillation.
The patient received 1 mg epinephrine, naloxone, and was
deﬁbrillated at 200 J twice before return of circulation about
15 min after CPR was initiated. Subsequent electrocardiogram
(ECG) showed ST segment elevation in the inferior and lateral leads
(Fig. 2) and the patient was taken directly to the cardiac
catheterization laboratory.s reserved.
Fig. 1. Angiogram showing non-obstructive coronary artery disease on day of presentation. LCA, left coronary artery; RCA, right coronary artery.
Fig. 2. Electrocardiogram showing ST-segment elevation in anteroseptal leads (V1–V5) on the day of presentation.
Table 1 Pertinent laboratory ﬁndings.
Laboratory parameter
(units)
Day 0
(on arrival)
Day 0 (prior to 2nd
cardiac arrest)
Sodium (mmol/l) 138 142
Potassium (mmol/l) 3.9 4.0
Chloride (mmol/l) 101 112
Bicarbonate (meq/l) 13.7 12.4
pH 7.22
Creatinine (mg/dl) 0.9 0.6
Glucose (mg/dl) 327 226
Calcium (mg/dl) 8.9 7.3
Magnesium (mg/dl) 2.0 2.2
Phosphorous (mg/dl) 3.3
Troponin T (ng/ml) 0.3
Lactate (mmol/l) 5.5
INR 1.05 1.13
Hemoglobin (g/dl) 14.8 14.3
Hematocrit (%) 45.9 42.8
Platelet (1000/ul) 209 189
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coronary artery, a 60% left anterior descending (LAD) artery
stenosis and a 70% right coronary arterial (RCA) ostial stenosis
(Fig. 1). The LAD and RCA lesions were interrogated by fractional
ﬂow reserve and found to be 0.84 and 0.86 respectively, consistent
with non-obstructive coronary disease. An initial transthoracic
echocardiogram (TTE) immediately post-arrest demonstrated
global hypokinesis with relative sparing of the inferior and
inferoseptal walls and an ejection fraction of 25–30%. Drastic ST
elevations on ECG without culprit lesions on diagnostic coronary
angiography performed suggested coronary spasm. Provocative
testing was not pursued in this case given additional associated
risks including sustained ventricular tachycardia and cardiac
tamponade in up to 1.3% of patients [5]. Pertinent laboratory
parameters were within normal limits (Table 1).
The patient was transferred to the cardiac intensive care unit
(CICU) for initiation of therapeutic hypothermia (TH). Shortly upon
transfer to the CICU, prior to initiation of TH, she experienced
another episode of ventricular ﬁbrillation cardiac arrest. Following
the ACLS algorithm, resuscitation efforts were performed with
chest compressions, delivery of two shocks at 200 J, administration
of 300 mg of amiodarone, 4 mg of epinephrine (in 1 mg increments
at 3 to 5-minute intervals), 40 units of vasopressin (administered
3 min after the initial 1 mg epinephrine dose), and 150 total
milliequivalents of sodium bicarbonate. After delivery of the
second shock, rhythm transitioned to pulseless electrical activity
with continuation of resuscitation efforts. After 27 min of
resuscitation efforts without return of spontaneous circulation,we decided to administer 200 mcg of NTG as an i.v. bolus as a last
resort. A second i.v. bolus of NTG 400 mcg was administered within
1 min of the initial NTG bolus, while resuscitation efforts were
continued. Within 6 min of the second i.v. NTG bolus administra-
tion, return of spontaneous circulation was achieved. A NTG i.v.
infusion was initiated at 0.15 mcg/kg/min to control vasospasm,
norepinephrine i.v. infusion at 0.4 mcg/kg/min to maintain mean
arterial pressure >60 mmHg, and amiodarone i.v. infusion at 1 mg/
min for recurring ventricular arrhythmia.
Fig. 3. Electrocardiogram showing resolution of ST-segment elevation on day #2 of hospitalization.
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noted to have bloody secretions from her endotracheal tube and
required airway pressure release ventilation settings to maintain
oxygenation. Due to the need to avoid paralysis with this ventilator
mode, wanting to avoid coagulopathy in the setting of the bloody
secretions,and concernthat moderatehypothermia(32–34 8C)could
exacerbate coronary vasospasm, the decision was made to start
modiﬁed (mild) TH with a target temperature of 36 8C. On day 2 of
admission, ECG showed resolution of ST-segment elevation (Fig. 3).
After 24 h of NTG i.v. infusion, she was transitioned to a
nicardipine i.v. infusion at 2.5 mg/h and later transitioned to oral
nifedipine 10 mg every 8 h. Prior to discharge, she was transitioned
from oral nifedipine to amlodipine 5 mg once daily. The patient
had no episodes of hypertension. However, she was optimized for
coronary artery disease and cardiomyopathy with aspirin 81 mg
daily, atorvastatin 40 mg daily, lisinopril 5 mg daily, and extended-
release metoprolol 25 mg daily.
She had no recurrent episodes of ventricular ﬁbrillation. Within
48 h of her presentation, she was showing signs of meaningful
neurologic activity and by the end of her hospitalization, her mental
status had returned to baseline. Prior to discharge, she had a cardiac
magnetic resonance imaging, which did not show any evidence of
inﬁltrative disease and showed similar wall motion abnormalities as
the aforementioned TTE. She received a single lead automatic
implantable cardioverter deﬁbrillator given the possibility of future
recurrence and depressed ejection fraction. The patient was
successfully discharged on day 14 of hospitalization.
Discussion
Cardiac arrest secondary to myocardial ischemia as a result of
coronary vasospasm has been well documented in the clinical
literature [6]. In our case, TTE demonstrated regional wall motion
abnormalities but the absence of obstructive coronary disease was
conﬁrmed with diagnostic angiography.
Coronary vasospasm has been attributed to either the hyper-
reactivity of vascular smooth muscle cells (VSMCs) or a vasocon-
strictor stimulus acting on the hyper-reactive VSMCs [6]. Vasodi-
lators including nitrates and calcium channel antagonists are the
standard treatment for coronary vasospasm [6]. While relatively
uncommon, misoprostol was likely the vasoconstrictor stimulus
culpable for the hyper-reactive VSMCs in this case.
A 2009 case report described an incidence of acute myocardial
infarction due to coronary vasospasm induced by misoprostol, a
synthetic prostaglandin E (PGE)1 analog administered intravaginally,and sulprostone, a synthetic PGE2 analog [7]. Eight hours after
administration of 5 intravaginal doses of misoprostol and an i.v. dose
of sulprostone, the patient complained of acute left-sided chest pain
and nausea [7]. An ECG was performed and ST elevation was reported
in inferior electrocardiographic leads (II, III, and aVF) with reciprocal
ST depression in the anterior leads [7]. Coronary angiography
demonstrated stenosis in the RCA, which subsequently resolved after
administration of 400 mcg intracoronary NTG [7]. A follow-up ECG
showed complete resolution of ST elevation [7].
In our case, reported use of misoprostol was within hours of
cardiac arrest. The mechanism for prostaglandin-mediated con-
tractility of coronary arteries remains unclear although probable
mechanisms include activation of G protein-coupled receptor,
speciﬁcally subtypes EP1 and EP3, responsible for vasoconstriction
[7,8]. In the present case, high-dose i.v. NTG during a ventricular
ﬁbrillation cardiac arrest in the setting of prostaglandin use, aided
in the return of spontaneous circulation.
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